Treatment of cytomegalovirus infection
AssigneeAllelix Biopharmaceuticals Inc.
InventorsMichael Twist, deceased, Martin Sumner-Smith
Life of this patent
Estimating the term…
Abstract
Described herein are anti-cytomegalovirus peptides. In a preferred embodiment, the peptide is acetyl-[D-Arg].sub.9 -NH.sub.2. The use of these peptides, either per se or in combination with other anti-CMV compounds, is disclosed as an effective method for controlling CMV infection.
Claims15
A method for treating a mammal having a cytomegaloviral infection, comprising the step of administering to said mammal a therapeutically effective amount of a peptide of the formula:
- R1--[X]--R2
- wherein
- R1 is H or an N-terminal protecting group;
- R2 is OH or a C-terminal protecting group;
- and
- X represents an oligopeptide consisting of `n` amino acids, wherein
- n is an integer from 6 to 12, said oligopeptide having a net positive charge of `n`, `n-1` or `n-2`, wherein said oligopeptide comprises at least six arginine residues and no less than n-3 arginine residues and consists essentially of D-amino acids.
A method for treating a mammal having a cytomegaloviral infection, comprising the step of administering to said mammal a therapeutically effective amount of a peptide of the formula:
- R1--[X]--R2
- wherein
- R1 is H or an N-terminal protecting group;
- R2 is OH or a C-terminal protecting group;
- and
- X represents 9 D-arginine residues.
Dependencies are inferred from the claim text.